GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Balaxi Pharmaceuticals Ltd (NSE:BALAXI) » Definitions » Debt-to-Equity

Balaxi Pharmaceuticals (NSE:BALAXI) Debt-to-Equity : N/A (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Balaxi Pharmaceuticals Debt-to-Equity?

Balaxi Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Balaxi Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Balaxi Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Balaxi Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

NSE:BALAXI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.08   Max: 0.15
Current: 0.15

During the past 10 years, the highest Debt-to-Equity Ratio of Balaxi Pharmaceuticals was 0.15. The lowest was 0.01. And the median was 0.08.

NSE:BALAXI's Debt-to-Equity is ranked better than
64.31% of 821 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs NSE:BALAXI: 0.15

Balaxi Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Balaxi Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Balaxi Pharmaceuticals Debt-to-Equity Chart

Balaxi Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.06 0.03 0.07 0.10

Balaxi Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.10 N/A 0.15 N/A

Competitive Comparison of Balaxi Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Balaxi Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Balaxi Pharmaceuticals's Debt-to-Equity falls into.


;
;

Balaxi Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Balaxi Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Balaxi Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Balaxi Pharmaceuticals  (NSE:BALAXI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Balaxi Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Balaxi Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Balaxi Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.

Balaxi Pharmaceuticals Headlines

No Headlines